Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer

Phase 4

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Erlotinib
Drug: Gefitinib
Drug: Icotinib
Drug: Docetaxel
Drug: Pemetrexed
Drug: Platinum (cisplatin or carboplatin)

First Posted Date: 2014-01-09

Last Posted Date: 2016-03-29

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 250

Registration Number: NCT02031601

Locations: 🇨🇳
Yu Li, Jinan, Shandong, China

A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer

Phase 2

Withdrawn

Conditions: Cancer of Head and Neck

Interventions: Drug: Omeprazole
Drug: Carboplatin
Drug: 5FU
Drug: Paclitaxel
Drug: Pemetrexed

First Posted Date: 2013-12-17

Last Posted Date: 2014-12-02

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT02013453

Locations: 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States

Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB

Phase 3

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Docetaxel
Drug: Pemetrexed
Drug: Cis-platinum
Drug: rh-Endostatin

First Posted Date: 2013-12-04

Last Posted Date: 2013-12-04

Lead Sponsor: Xinjiang Medical University

Target Recruit Count: 392

Registration Number: NCT02001168

Locations: 🇨🇳
Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Tepotinib
Drug: Pemetrexed
Drug: Gefitinib
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2013-11-13

Last Posted Date: 2022-11-08

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 88

Registration Number: NCT01982955

Locations: 🇨🇳
Jilin University, Changchun, China
🇨🇳
Jilin Cancer Hospital, Changchun, China
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, China

and more 41 locations

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Terminated

Conditions: Recurrent Non-Small Cell Lung Carcinoma
Stage IV Non-Small Cell Lung Cancer
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Non-Small Cell Lung Cancer

Interventions: Drug: Azacitidine
Drug: Docetaxel
Drug: Entinostat
Drug: Gemcitabine Hydrochloride
Drug: Irinotecan Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Pemetrexed Disodium

First Posted Date: 2013-09-05

Last Posted Date: 2018-07-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT01935947

Locations: 🇺🇸
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

and more 2 locations

Nintedanib (BIBF 1120) in Mesothelioma

Phase 2

Terminated

Conditions: Mesothelioma

Interventions: Drug: Pemetrexed
Drug: Nintedanib
Drug: Cisplatin
Drug: Placebo

First Posted Date: 2013-07-24

Last Posted Date: 2019-03-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 545

Registration Number: NCT01907100

Locations: 🇦🇺
Northern Cancer Institute, St Leonards, New South Wales, Australia
🇺🇸
Texas Oncology - McAllen, McAllen, Texas, United States
🇺🇸
Cancer Care Northwest Centers, PS, Spokane Valley, Washington, United States

and more 119 locations

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Phase 2

Active, not recruiting

Conditions: Medulloblastoma

Interventions: Radiation: Craniospinal Irradiation with boost to the primary tumor site
Drug: Cyclophosphamide
Drug: Cisplatin
Drug: Vincristine
Other: Aerobic Training
Drug: Vismodegib
Drug: Pemetrexed
Other: Neurocognitive Remediation
Drug: Gemcitabine

First Posted Date: 2013-06-17

Last Posted Date: 2024-11-26

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 660

Registration Number: NCT01878617

Locations: 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸
Texas Children's Cancer Center, Houston, Texas, United States
🇺🇸
Children's Hospital and Clinics of Minnesota, Minneapolis, Minnesota, United States

and more 20 locations

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: GSK3052230
Drug: paclitaxel
Drug: pemetrexed
Drug: docetaxel
Drug: cisplatin
Drug: carboplatin

First Posted Date: 2013-06-04

Last Posted Date: 2019-08-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 65

Registration Number: NCT01868022

Locations: 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom

Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

Phase 2

Terminated

Conditions: Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer
Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer

Interventions: Drug: Cisplatin
Drug: Gemcitabine
Drug: Pemetrexed

First Posted Date: 2013-05-22

Last Posted Date: 2018-02-07

Lead Sponsor: Western Regional Medical Center

Target Recruit Count: 1

Registration Number: NCT01860040

Locations: 🇺🇸
Western Regional Medical Center, Goodyear, Arizona, United States

Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer (Squamous or Non Squamous)

Interventions: Drug: Pemetrexed
Drug: Gemcitabine
Drug: Induction chemotherapy

First Posted Date: 2013-05-09

Last Posted Date: 2023-03-14

Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique

Target Recruit Count: 632

Registration Number: NCT01850303

Locations: 🇫🇷
Metz - Belle Isle, Metz, France
🇫🇷
Hôpital de Cholet - Pneumologie, Cholet, France
🇫🇷
Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France

and more 74 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy